You are here

Clinical and Applied Thrombosis/Hemostasis
Share

Clinical and Applied Thrombosis/Hemostasis

2016 Impact Factor: 2.096
2016 Ranking: 43/70 in Hematology | 44/63 in Peripheral Vascular Disease
Source: 2016 Journal Citation Reports® (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE



eISSN: 19382723 | ISSN: 10760296 | Current volume: 23 | Current issue: 6 Frequency: 8 Times/Year

An Indispensable Asset in the Treatment and Management of Bleeding and Clotting Disorders

From January 2018, Clinical and Applied Thrombosis/Hemostasis will publish all new content open access.
Therefore, articles first submitted on or after 1st August 2017 will be subject to an open access article process charge (APC), if accepted after peer review. An introductory APC of 1,000 USD, discounted from the full rate of 2,000 USD, is available for a limited time. Published papers will be made open access immediately with a Creative Commons licence which enables authors to retain copyright of their work and allows liberal reuse. Papers first submitted before 1st August 2017 will not be charged.

Every issue of Clinical and Applied Thrombosis/Hemostasis (CATH) addresses the practical clinical and laboratory issues involved in managing bleeding and clotting disorders, especially those related to thrombosis, hemostasis, and vascular disorders. CATH offers comprehensive coverage of the topics that matter most to your work, including clinical trials, studies on etiology, pathophysiology, diagnosis and treatment of thrombohemorrhagic disorders, assessment of new clinical diagnostic procedures, pharmacological agents, laboratory diagnostic procedures, and patient management plans. CATH continually evaluates new research in areas including essential drugs such as Warfarin, Heparin, low-molecular-weight Heparin, and other emerging drug therapies; the clinical impact on treatment of diseases and conditions such as diabetes, hypertension, pregnancy, hemophilia, and HIV-AIDS; factor defects; platelet disorders; fibrinolytic disorders; DNA/RNA research; and ethnic and population differences in thrombohemorrhagic disorders.

Rigorously peer-reviewed and well cited, Clinical and Applied Thrombosis/Hemostasis presents original research reports, review articles, case reports, and book/media reviews that expand your clinical perspective and help improve your clinical diagnostic skills. Some of the latest advances discussed in recent issues include

  • Coagulation and Fibrinolysis in Preeclampsia and Neonates
  • Differentiation of Low-Molecular-Weight Heparins: Practical Implications
  • Disseminated Intravascular Coagulation Syndromes
  • Effect of Antihypertensive Treatment on Plasma Fibrinogen and Serum HDL Levels
  • Evaluation of New Japanese Diagnostic Criteria for Disseminated Intravascular Coagulation in Critically Ill Patients
  • Iron Deficiency and Thrombosis: Literature Review
  • Oral Contraceptives and Thrombosis
  • Pitfalls in Warfarin Therapy
  • Platelet Function and Fibrinolytic Activity
  • Prevention of Venous Thrombosis and Thrombophlebitis in Long-Haul Flights with Pycnogenol®
  • Severe Thrombotic Microangiopathy and Plasmapheresis
  • Spectrum of Inherited Bleeding Disorders in Indians
  • Sticky Platelet Syndrome
  • Transitioning from Argatroban to Warfarin Therapy in Patients with Heparin-induced Thrombocytopenia


This journal is a member of the Committee on Publication Ethics (COPE).

Clinical and Applied Thrombosis/Hemostasis (CATH) is dedicated to serving as a forum for studies regarding the etiology, pathophysiology, clinical diagnosis, laboratory diagnosis, and treatment of thrombohemorrhagic disorders. Articles dealing with new diagnostic procedures are encouraged, provided they are clinically oriented or potentially applicable to clinical and laboratory medicine. Articles dealing with all aspects of thrombosis, hemostasis, and vascular disorders of clinical or clinical laboratory applicability are also encouraged. The contents of the journal appeal to any person interested in clinical and applied thrombohemorrhagic disorders.

From January 2018, Clinical and Applied Thrombosis/Hemostasis will publish all new content open access. Therefore, articles first submitted on or after 1st August 2017 will be subject to an open access article process charge (APC), if accepted after peer review. An introductory APC of 1,000 USD, discounted from the full rate of 2,000 USD, is available for a limited time. Authors paying the APC will enjoy the benefits of immediate, full open access publishing and will utilize one of the Creative Commons licenses which enable them to retain copyright.

Managing Editor
Senior Editors
William Baker, Jr. MD, FACP  
Jawed Fareed, Ph.D Loyola University Chicago, USA
Esteban Gandara The Ottowa Hospital, General Campus, Canada
Deborah Hoppensteadt, Ph.D Loyola University Chicago, USA
Evi Kalodiki Ealing Hospital, UK
Nicos Labropoulos USA
Qing Ma New York University at Buffalo, Buffalo, NY, USA
Graham Pineo, M.D. University of Calgary, Canada
Jeanine M. Walenga, Ph.D Loyola University Medical Center, Maywood, IL, USA
Senior European Editors
Antonio Girolami, M.D. University of Padua, Italy
Sylvia Haas, MD Munich, Germany
Walter Jeske, Ph.D Loyola University Medical Center, Maywood, IL, USA
Wolfgang Miesbach Universitätsklinikum Frankfurt, Germany
Hideo Wada, M.D. Mie University, Japan
Mediterranean Editor
Muzaffer Demir, M.D. Trakya University, Turkey
Editorial Board Members
Raul Altman, M.D. Buenos Aires, Argentina
H. Peter Bacher, M.D., Ph.D Long Grove, IL, USA
Gianni Belcaro, M.D., Ph.D Pelcara, Italy
Samuel Berkman, M.D., FACP Bevery Hills, CA, USA
Charles A. Carter Pharmaceutical Strategic Initiatives, USA
Anthony K. Chan McMaster University, Canada
Sergio Coccheri Bologna, Italy
Charles J. Glueck, M.D. Cholesterol Center, ABC Building
Lothar Heilmann Russelheim, Germany
Joseph Heissler, Jr., Pharm.D Pfizer Global Pharmaceuticals, USA
Mohammad Jamshidi, DO, FACS Millennia Care Clinic, TX, USA
Valery Leytin, Ph.D St. Michael’s Hospital, Toronto, Canada
Dimitri P. Mikhailidis, M.D., FRCPATH Royal Free and University College Medical School, UK
Michael Mosesson, M.D. University of Wisconsin, USA
Bali Netaji, M.D. Southwest Regional Cancer Center, Australia
Andrew N. Nicolaides  
William F. Pope Dallas, TX, USA
Alice Runge, M.T. Santa Monica, CA, USA
Arthur Sasahara, M.D. Boston, MA, USA
Renu Saxena  
Georg-Friedrich von Tempelhoff, M.D. City Hospital of Ruesselshein, Germany
Oran Ulutin, M.D. Istanbul, Turkey
David H. Van Thiel, M.D.  
James Wilson, M.D. Texas Medical Center, USA
  • Clarivate Analytics: Current Contents - Clinical Medicine
  • Clarivate Analytics: Science Citation Index
  • EMBASE/Excerpta Medica
  • Inpharma Database
  • MEDLINE
  • Ovid: Allied and Complementary Medicine Database
  • Reactions Database
  • SciSearch
  • Science Citation Index Expanded (Web of Science)
  • From January 2018, the Clinical and Applied Thrombosis/Hemostasis will publish all content open access. Therefore, articles first submitted on or after August 1, 2017 will be subject to an open access article process charge (APC), if accepted after peer review. An introductory APC of $1000 USD, discounted from the full rate of $2000 USD, is available for a limited time. Authors paying the APC will enjoy the benefits of immediate, full open access publishing and will utilize one of the Creative Commons licenses which enable them to retain copyright.

    Accepted papers first submitted before August 1st, 2017 will not be charged.

    This Journal recommends that authors follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

    Please read the full author guidelines for Clinical and Applied Thrombosis/Hemostasis at this link, then visit the Journal’s submission site: https://mc.manuscriptcentral.com/cath to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.

    Only manuscripts of sufficient quality that meet the aims and scope of Clinical and Applied Thrombosis/Hemostasis will be reviewed.

    Clinical and Applied Thrombosis/Hemostasis will publish manuscripts submitted on or after August 1st under Creative Commons licenses. The standard license is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page.

    Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.

    Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Clinical and Applied Thrombosis/Hemostasis editorial office as follows:

    Sheila Platt, Editorial Manager
    Email: sheilaplatt@optonline.net

    Individual Subscription, Print Only


    Institutional Backfile Purchase, E-access (Content through 1998)


    Institutional Subscription, Print Only


    Individual, Single Print Issue


    Institutional, Single Print Issue